Northwestern Medicine and Tempus AI (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI Reports Strong Preliminary 2025 Revenue Growth
- Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges
- Tempus AI announced TCV of more than $1.1B
- Tempus AI price target lowered to $76 from $88 at TD Cowen
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU